The objectives of this trial are to: To determine if 9-aminocamptothecin CD administered as a 120h weekly infusion is an effective agent of treatment of advanced non-small cell lung cancer. To observe the toxicity associated with this regimen among patients with advanced nonsmall cell lung cancer. To measure the levels of topoisomerase I in tumor biopsy specimens obtained from patients with non small cell lung cancer entered on this trial. To determine the 9-AC pharmacokinetics parameters and to correlate serum levels with toxicity and response to treatment. To determine the mutagenic potential of 9-AC administered as a 120hr weekly infusion.""""""""
Showing the most recent 10 out of 753 publications